Healthcare Triangle, Inc. HCTI PHARMA
Company Overview
Healthcare Triangle, Inc., a healthcare information technology company, focuses on advancing solutions in the sectors of cloud services, data science, and professional and managed services for the electronic health record, and healthcare and life sciences industry. It provides a suite of software, solutions, platforms, and services that enables healthcare and pharma organizations to deliver personalized healthcare, precision medicine, advances in drug discovery, development and efficacy, collaborative research and development, respond to evidence, and accelerate their digital transformation. The company's software platforms include CloudEz, an enterprise multi-cloud transformation and management platform that enables customers to manage their cloud infrastructure in private, hybrid, and public cloud infrastructures; DataEz, a cloud-based data analytics and data science platform for the data analytics and data science requirements of life sciences/pharmaceutical and healthcare provider organizations; Blockchain infrastructure; and Cybersecurity navigator. It also provides Readabl.AI, a Software-as-a-Service solution that uses public cloud artificial intelligence and machine learning to recognize and extract healthcare information from documents, faxes, and narrative reports. In addition, the company offers cloud IT services; and healthcare IT services, such as electronic health records and software implementation, optimization, and extension to community partners, as well as application managed services, and backup and disaster recovery capabilities on public cloud. It also serves healthcare delivery organizations, healthcare insurance companies, pharmaceutical and life sciences, biotech companies, and medical device manufacturers. Healthcare Triangle, Inc. was incorporated in 2019 and is based in Pleasanton, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.26.
Recent Developments
- Dec 2025 Revenue of $13.89M (+18.8% YoY); net profit $-9.48M.
- Trailing 12 Months Year-on-year growth — revenue +158.4%.
- 5-Year Trend Long-term compounding — revenue CAGR -15.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -15.02% |
| 1 Year: | 158.40% |
Stock Price Performance
| 1 Year: | -99.59% |
| 6 Months: | -71.14% |
| 3 Months: | -65.14% |
| 1 Month: | -36.98% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)33.83 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -15.0% CAGR over 5 years.
- Trading 99.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HCTI Healthcare Triangle, Inc. PHARMA | 0.79 | -0.14 | $11.57M | 0.00% | -98.44% | -57.40% | -15.02% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.36M | 7.95M | 10.05M | 8.08M | 11.06M | 11.59M | 11.95M | 9.84M | 8.53M | 7.78M | 4.11M | 2.98M | 2.41M | 3.70M | 3.56M | 3.49M | 3.14M | 9.86M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.38M | 3.06M | 2.87M | 2.69M | 7.46M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 1.07B | - | - | 329.00K | 494.00K | 618.00K | 448.00K | 2.39M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.73M | 1.85M | 3.21M | 4.87M | 5.89M |
| Operating Income | 191.31K | -716.00K | 469.00K | -1.77M | -1.97M | -1.43M | -2.25M | -3.21M | -1.59M | -1.52M | -1.71M | -1.38M | -1.17M | -1.40M | -1.36M | -2.59M | -4.43M | -3.50M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.27M | -1.35M | -1.81M | -3.77M | -5.30M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 413.00K | 21.00K | 32.00K | 100.00K | 85.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.70M | -1.37M | -1.91M | -4.50M | -6.20M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | 138.81K | -814.00K | 304.00K | -1.99M | -2.01M | -405.00K | -2.34M | -3.28M | -1.79M | -1.94M | -1.86M | -1.51M | -1.25M | -1.70M | -1.37M | -1.91M | -4.50M | -6.20M |
| Diluted EPS | 0.01 | -0.03 | 0.01 | -0.07 | -0.06 | -0.01 | - | -0.79 | -0.42 | -0.45 | -0.42 | -70.72 | -54.78 | -561.80 | -34.80 | -25.73 | - | -6.66 |
| R&D Expense | 550.17K | 757.00K | 813.00K | 2.20M | 1.07M | 646.00K | 1.47M | 539.00K | 102.00K | 54.00K | 127.00K | 207.00K | 175.00K | 144.00K | 55.00K | 59.00K | - | 85.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 31.34M | 35.27M | 45.89M | 33.20M | 11.70M | 13.89M |
| Gross Profit | - | - | - | 1.07B | 1.07B | 1.24B |
| Operating Income | 1.18M | -5.36M | -10.42M | -7.70M | -4.75M | -9.79M |
| Net Income | 2.35M | -5.95M | -9.61M | -8.69M | -5.97M | -9.48M |
| Diluted EPS | 0.08 | -0.20 | -2.63 | -2.08 | -16,909.30 | -152.30 |
| R&D Expense | 1.74M | 5.26M | 5.95M | 799.00K | 429.00K | 536.00K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 11.11M | 24.61M | 20.76M | 6.86M | 1.96M | 22.74M |
| Total Equity | 1.97M | 4.33M | 16.14M | 6.04M | -1.39M | -5.11M | 9.94M |
| Cash & Equivalents | 974.83K | 1.40M | 1.77M | 1.34M | 1.23M | 20.00K | 7.62M |
| Total Liabilities | - | 6.78M | 8.48M | 8.38M | 8.25M | 7.08M | - |
| Current Liabilities | - | 6.78M | 6.25M | 6.15M | 8.15M | 7.08M | 12.79M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -734.67K | -7.11M | -2.60M | -2.15M | -1.08M | -16.52M |
| Investing Cash Flow | -477.46K | -7.63M | -3.32M | -12.00K | - | -1.75M |
| Financing Cash Flow | 1.64M | 15.11M | 5.49M | 2.06M | -133.00K | 25.88M |
| Capital Expenditure | - | - | -40.00K | -12.00K | - | -6.00K |
| Free Cash Flow | - | - | -2.64M | -2.16M | - | -16.53M |
| Share Buybacks | - | - | 142.00K | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 3,222.6% | 9,148.4% | 8,890.6% |
| Operating Margin % | 3.8% | -15.2% | -22.7% | -23.2% | -40.6% | -70.5% |
| Net Margin % | 7.5% | -16.9% | -20.9% | -26.2% | -51.0% | -68.2% |
| ROE % | 54.4% | -36.9% | -159.1% | 624.4% | 116.7% | -95.3% |
| ROCE % | 27.2% | -29.2% | -71.3% | 594.7% | 92.9% | -98.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bank of Montreal /CAN/ | 0.13% | 20.00K | $15.50K |
| 2 | Geode Capital Management, LLC | 0.08% | 11.97K | $9.28K |
| 3 | UBS Group AG | 0.06% | 8.86K | $6.87K |
| 4 | Tower Research Capital LLC (TRC) | 0.01% | 1.31K | $1.02K |
| 5 | Vanguard Capital Management LLC | 0.01% | 859 | $665 |
| 6 | Danske Bank A/s | - | 1 | $0 |
| 7 | JPMORGAN CHASE & CO | - | 20 | $15 |
| 8 | Barclays Plc | - | 310 | $240 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HCTI
Healthcare Triangle, Inc. to Distribute Minority Interest of Teyame AI Holdings Inc. Common Shares in Stock Dividend Distribution to HCTI Shareholders, In Connection with its Planned Direct Listing. - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQb082MVBCLTdfczNQNzRFbDlmenZHdjI2VGU0akNPQVhXeHJBSkJCVVkyZlNoeHlQR1F2RHdBcGFWVm5VUC1FY25tc24tcUg0NEFKYzVUd011amFGXzhQMGxaRUNDZGd6NEthVFNaU1JGUzNVUGdSYzlRa0pkUFFXXzFrVU1iV3dzNUZhZW…
Gapping stocks in Thursday's session - ChartMill
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNU0kyUkxRNVRJNzFaMGdGb3JLczFXS1l4YUdWMUdjSHZMcjR5bE1LNGpEN240SzR6UlFYNjE5V0ZWQWVVUFdIZ096NDJ4UHFuRkJRTjMyZ2d6VS04R1R2bndiclFyUUtJaUFaRDZCZU5rMzdXd1prbXVBaGVYYWdfcmRVb2tmbVA1eHJHSm…
HCTI - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5wMjR0U0kycGM3RlVleEZOX0xfeGVJcmxSUk9MTFEyd0xwQ1BldjFNWlFiaDlGbld5SUw2RzhnUjhmcVZvcWc?oc=5" target="_blank">HCTI</a> <font color="#6f6f6f">Finviz</font>…
Purpose Health CEO brings $175M scaling record to healthcare AI - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQaXE3M0F6Vkk2cFlOWTRnWDdLUTNMZXdUd19QbUZ0WHJpU09WMk53TnZWaUN4QlpaN0dtNVc1VzFfazllVjVVUDMwX0VjRk9JTFlfTTQwZFd6Qi1wRU5HZUlhQ2xhTHdfZWNGOHZXdkh5Mjk4bU1IODNDOWZyVUwtNGpwd2ZsZmFfOUJJV2…
Healthcare Triangle Completes Share Issuances Relating to Legacy M&A Transactions, Strengthening Compliance With Nasdaq's New $5 Million Market Value Listing Standard - Eastern Progress
<a href="https://news.google.com/rss/articles/CBMiqAJBVV95cUxQNnlKamNjVlZBMWZsQUxJWm5Oem5nU044Z2JwTDRROG80OUh0Rlh3QnRfS0dHNFc1TWg1RzdneUJVbGVHWXZkNXQ1dExyWk1neTM2NlJaZDJlVGZsM1NUenVZd0s0RjRObFVkLXZKVFJZSzc2ZnBWMFpvMVROSEE3UkRVSUZ4UG9kalVoWX…
Healthcare Triangle (HCTI) Stock Surges Over 36% After Hours: Here's What You Should Know - Benzinga
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPM3dnZkhXcDNSV3pjUXV6MGpnakFkaTI1eWpyRE9hZ3RIUzdVdlJHN25kUWplRUtwdEpvUEloWC1UVUg5SWZXVmpxd2w0ZzR5WVBHU0NpTS1qbjY2SWpaREVIQVVpdGxDTVk1SzExS3FMdHluR0VmSWthWWljUi1hcVo3SV9jYjMtVU5xcU…
HCTI — Frequently Asked Questions
What is the current share price of Healthcare Triangle, Inc. (HCTI)?
As of 2026-09-19 21:16 PDT, Healthcare Triangle, Inc. (HCTI) trades at $0.79 on NasdaqCM. Its 52-week range is $0.79 to $239.40.
What is the market capitalisation of HCTI?
Healthcare Triangle, Inc. (HCTI) has a market capitalisation of $11.57M on NasdaqCM.
What is the P/E ratio of HCTI?
HCTI trades at a trailing price-to-earnings (P/E) ratio of -0.14. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.07.
What is the return on equity (ROE) of HCTI?
HCTI has a return on equity (ROE) of -57.40%. Its return on capital employed (ROCE) is -98.44%.
Is HCTI a good stock to buy?
This page provides a data-driven analysis of Healthcare Triangle, Inc. (HCTI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.